<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychiatr Dis Treat</journal-id>
<journal-id journal-id-type="publisher-id">Neuropsychiatric Disease and Treatment</journal-id>
<journal-title-group>
<journal-title>Neuropsychiatric Disease and Treatment</journal-title>
</journal-title-group>
<issn pub-type="ppub">1176-6328</issn>
<issn pub-type="epub">1178-2021</issn>
<publisher>
<publisher-name>Dove Medical Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27110117</article-id>
<article-id pub-id-type="pmc">4835132</article-id>
<article-id pub-id-type="doi">10.2147/NDT.S101580</article-id>
<article-id pub-id-type="publisher-id">ndt-12-843</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Medhasi</surname>
<given-names>Sadeep</given-names>
</name>
<xref ref-type="aff" rid="af1-ndt-12-843">1</xref>
<xref ref-type="aff" rid="af2-ndt-12-843">2</xref>
<xref ref-type="aff" rid="af3-ndt-12-843">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pasomsub</surname>
<given-names>Ekawat</given-names>
</name>
<xref ref-type="aff" rid="af4-ndt-12-843">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vanwong</surname>
<given-names>Natchaya</given-names>
</name>
<xref ref-type="aff" rid="af1-ndt-12-843">1</xref>
<xref ref-type="aff" rid="af2-ndt-12-843">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ngamsamut</surname>
<given-names>Nattawat</given-names>
</name>
<xref ref-type="aff" rid="af5-ndt-12-843">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Puangpetch</surname>
<given-names>Apichaya</given-names>
</name>
<xref ref-type="aff" rid="af1-ndt-12-843">1</xref>
<xref ref-type="aff" rid="af2-ndt-12-843">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chamnanphon</surname>
<given-names>Montri</given-names>
</name>
<xref ref-type="aff" rid="af1-ndt-12-843">1</xref>
<xref ref-type="aff" rid="af2-ndt-12-843">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hongkaew</surname>
<given-names>Yaowaluck</given-names>
</name>
<xref ref-type="aff" rid="af1-ndt-12-843">1</xref>
<xref ref-type="aff" rid="af2-ndt-12-843">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Limsila</surname>
<given-names>Penkhae</given-names>
</name>
<xref ref-type="aff" rid="af5-ndt-12-843">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinthong</surname>
<given-names>Darawan</given-names>
</name>
<xref ref-type="aff" rid="af3-ndt-12-843">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sukasem</surname>
<given-names>Chonlaphat</given-names>
</name>
<xref ref-type="aff" rid="af1-ndt-12-843">1</xref>
<xref ref-type="aff" rid="af2-ndt-12-843">2</xref>
<xref ref-type="corresp" rid="c1-ndt-12-843"></xref>
</contrib>
</contrib-group>
<aff id="af1-ndt-12-843"><label>1</label>Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</aff>
<aff id="af2-ndt-12-843"><label>2</label>Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</aff>
<aff id="af3-ndt-12-843"><label>3</label>Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand</aff>
<aff id="af4-ndt-12-843"><label>4</label>Division of Virology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</aff>
<aff id="af5-ndt-12-843"><label>5</label>Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department of Mental Health Services, Ministry of Public Health, Samut Prakarn, Thailand</aff>
<author-notes>
<corresp id="c1-ndt-12-843">Correspondence: Chonlaphat Sukasem, Division of Pharmacogenetics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270, Rama 6 Road, Thung Phaya Thai, Ratchathewi, Bangkok, 10400, Thailand, Tel +66 2 200 4331, Fax +66 2 200 4332, Email <email>chonlaphat.suk@mahidol.ac.th</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>4</month>
<year>2016</year>
</pub-date>
<volume>12</volume>
<fpage>843</fpage>
<lpage>851</lpage>
<permissions>
<copyright-statement>© 2016 Medhasi et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement>
<copyright-year>2016</copyright-year>
<license>
<license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p>
</license>
</permissions>
<abstract>
<p>Single-nucleotide polymorphisms (SNPs) among drug-metabolizing enzymes and transporters (DMETs) influence the pharmacokinetic profile of drugs and exhibit intra- and interethnic variations in drug response in terms of efficacy and safety profile. The main objective of this study was to assess the frequency of allelic variants of drug absorption, distribution, metabolism, and elimination-related genes in Thai children and adolescents with autism spectrum disorder. Blood samples were drawn from 119 patients, and DNA was extracted. Genotyping was performed using the DMET Plus microarray platform. The allele frequencies of the DMET markers were generated using the DMET Console software. Thereafter, the genetic variations of significant DMET genes were assessed. The frequencies of SNPs across the genes coding for DMETs were determined. After filtering the SNPs, 489 of the 1,931 SNPs passed quality control. Many clinically relevant SNPs, including <italic>CYP2C</italic>19*2, <italic>CYP</italic>2<italic>D6</italic>*<italic>10</italic>, <italic>CYP3A5</italic>*<italic>3</italic>, and <italic>SLCO1B1*5</italic>, were found to have frequencies similar to those in the Chinese population. These data are important for further research to investigate the interpatient variability in pharmacokinetics and pharmacodynamics of drugs in clinical practice.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>Thai population</kwd>
<kwd>ADME</kwd>
<kwd>pharmacokinetics</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>microarray</kwd>
<kwd>pharmacogenetics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Autism spectrum disorder (ASD) is a global health concern where the patient demonstrates three core features: social withdrawal, verbal and nonverbal communication impairment, and stereotype behavior with restricted and repetitive activities and/or interests.<xref ref-type="bibr" rid="b1-ndt-12-843">1</xref> Results have shown that males are more likely to have autism than females, with a prevalence ratio of 4:1.<xref ref-type="bibr" rid="b2-ndt-12-843">2</xref>,<xref ref-type="bibr" rid="b3-ndt-12-843">3</xref> Atypical antipsychotics, including risperidone and aripiprazole, both US Food and Drug Administration approved, have been used as a pharmacologic therapy for the treatment of behavioral symptoms (irritability and aggression) in addition to the psychoeducational therapy among children and adolescents.<xref ref-type="bibr" rid="b4-ndt-12-843">4</xref>,<xref ref-type="bibr" rid="b5-ndt-12-843">5</xref> However, children and adolescents treated with antipsychotic drugs may be predisposed to side effects, such as weight gain, metabolic effects, endocrinal dysfunction, and tardive dyskinesia.<xref ref-type="bibr" rid="b6-ndt-12-843">6</xref>,<xref ref-type="bibr" rid="b7-ndt-12-843">7</xref> Genetic variations in drug-metabolizing enzymes (DMEs), drug transporters, and drug targets are important determinants of efficacy and toxicity in pharmacotherapy among patients.<xref ref-type="bibr" rid="b8-ndt-12-843">8</xref> Individual variability in drug response poses a major challenge in drug therapy, drug development, and drug regulation.<xref ref-type="bibr" rid="b9-ndt-12-843">9</xref> A better account of genetic variability and implementation of personalized medicine are essential in individual patients to improve the drug therapy by enabling clinicians to prescribe the right medication in the right dose to achieve maximum therapeutic efficacy with minimum adverse drug reactions.<xref ref-type="bibr" rid="b10-ndt-12-843">10</xref> Pharmacogenetics is the study of contribution of genetic differences to drug response between individuals. Advances in the field of molecular genotyping, such as DNA chips and microarrays, have facilitated the analysis of large genetic variations.<xref ref-type="bibr" rid="b11-ndt-12-843">11</xref> Single-nucleotide polymorphisms (SNPs) are an important marker for pharmacogenetic studies, which can be used for phenotypic association with a functional variant and for optimizing personalized drug therapy.<xref ref-type="bibr" rid="b12-ndt-12-843">12</xref>,<xref ref-type="bibr" rid="b13-ndt-12-843">13</xref> Investigations on animal models of autism have revealed the association between polymorphism in serotonin transporter (5-HTT) and autism.<xref ref-type="bibr" rid="b14-ndt-12-843">14</xref> In humans, genetic studies in patients with ASD have revealed the polymorphisms in <italic>CYP1A2</italic>*<italic>1F</italic> and its association with susceptibility to ASD,<xref ref-type="bibr" rid="b15-ndt-12-843">15</xref> and another polymorphism contributing to ASD is <italic>COMT</italic> Val58Met.<xref ref-type="bibr" rid="b16-ndt-12-843">16</xref></p>
<p>Polymorphisms in DMEs and transporters (DMETs) across different populations have been reported with varying frequencies of allelic variation, suggesting interethnic differences in response to drug therapy. Patients are classified as poor metabolizer (PM), intermediate metabolizer, extensive metabolizer, and ultrarapid metabolizer, leading to no activity, reduced activity, normal activity, and increased activity, respectively, based on the DME genetic polymorphisms.<xref ref-type="bibr" rid="b17-ndt-12-843">17</xref> The most common cytochrome P450 polymorphisms are found in <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and <italic>CYP2D6</italic> as identified to date (<ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se">http://www.cypalleles.ki.se</ext-link>). The important Phase II enzymes exhibiting genetic polymorphisms, which determine the fate of the drugs, include uridine diphosphate glucuronosyltransferase (UGT), glutathione <italic>S</italic>-transferase (GST), sulfotransferase, <italic>N</italic>-acetytransferase (NAT), and thioupurine methyltransferase (TPMT). Some of the best characterized drug transporter genes implicated in drug metabolism and response include the adenosine triphosphate (ATP)-binding cassette (ABC) family, such as <italic>ABCB1</italic>, <italic>ABCC1</italic>, <italic>ABCC2</italic>, and <italic>ABCG2</italic>, and solute carrier (SLC) family proteins, such as <italic>OCT1</italic>, <italic>OATP1B1</italic>, and <italic>OAT</italic>.<xref ref-type="bibr" rid="b18-ndt-12-843">18</xref>,<xref ref-type="bibr" rid="b19-ndt-12-843">19</xref> Several pharmacogenetic biomarkers of DMETs are documented in PharmGKB (<ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>), with evidence from different populations. There is a considerable difference in the frequency of genetic polymorphisms associated with drug response, across and within populations.<xref ref-type="bibr" rid="b20-ndt-12-843">20</xref> The DMET genes have greater interindividual variability in expression as compared to non-DMET genes.<xref ref-type="bibr" rid="b21-ndt-12-843">21</xref> A study investigating the frequencies of DMET SNPs among Thais as well as compared to other ethnic populations revealed significant differences in the distribution of several clinically important genetic polymorphisms among absorption, distribution, metabolism, and elimination genes.<xref ref-type="bibr" rid="b22-ndt-12-843">22</xref> Integrating pharmacogenetics into clinical practice has proven to be a cost-saving and improved therapeutic outcome for patients, with the avoidance of medication adverse effects.<xref ref-type="bibr" rid="b23-ndt-12-843">23</xref> There is a critical need to understand and establish the frequency of genetic variants and implement the knowledge of genetic variation in DMET genes in the Thai population to construct dosing guidelines, so as to improve the clinical efficacy and minimize the occurrence of adverse effects.</p>
<p>In this study, we used the DMET™ Plus GeneChip microarray platform (Affymetrix Inc., Santa Clara, CA, USA), which is used to genotype markers across genes involved in drug pharmacokinetics. The main aim of this study was to investigate the frequency of DMET genetic variations in the Thai population. The genetic database derived from this study will help in determining the pattern of SNPs in DMET genes among Thai population and correlate the genetic information with the drug response and adverse side effects to produce the significant clinical associations.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec sec-type="subjects">
<title>Participants</title>
<p>Blood samples were collected from the 119 Thai children and adolescents with ASD (according to the <italic>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</italic> criteria) at Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital. Participants were included who were prescribed with risperidone once or twice a day and the dosing was flexible as well. Patients with severe physical disabilities and currently being treated with other antipsychotic drugs were excluded from the study. However, stimulants were allowed in the case of co-occurring attention deficit/hyperactivity disorder. The purpose and experimental procedures were explained to the parents of the participants before obtaining written informed consent from all of the participants’ parents. The study was conducted in accordance with the principles of the Declaration of Helsinki and locally approved by the Ramathibodi Ethics Committee (Bangkok, Thailand).</p>
</sec>
<sec>
<title>Sample collection and genomic DNA (gDNA) extraction</title>
<p>Blood samples were collected into EDTA tubes with the assistance of a trained laboratory technician and were then brought to the laboratory of Pharmacogenomics and Personalized Medicine, Ramathibodi Hospital, in a well-insulated ice box. The samples were then stored at &lt;−70°C for the subsequent extraction of gDNA.</p>
<p>gDNA was isolated from EDTA–whole blood using a MagNA Pure Compact System (Hoffman-La Roche Ltd., Basel, Switzerland), according to the manufacturer’s instructions, and quantified by a NanoDrop™ 1000 Spectrophotometer at 260 nm (Thermo Fisher Scientific, Waltham, MA, USA).</p>
</sec>
<sec>
<title>Genotyping and marker selection</title>
<p>Samples were genotyped using the DMET platform (DMET Plus) according to the standard protocol described by the manufacturer. The DMET™ Plus GeneChip enables the genotyping of 1,936 genetic variants (1,931 SNPs and five copy number variations) of 231 genes having functional significance in Phase I and Phase II DME genes and drug transporter coding genes.<xref ref-type="bibr" rid="b20-ndt-12-843">20</xref> The DMET Plus platform examines the genetic variations, including biallelic and triallelic SNPs, copy number variations, and insertions/deletions.<xref ref-type="bibr" rid="b24-ndt-12-843">24</xref> Genotype analysis using the DMET Plus platform is based on an efficient and comprehensive molecular inversion probe technology.<xref ref-type="bibr" rid="b25-ndt-12-843">25</xref>,<xref ref-type="bibr" rid="b26-ndt-12-843">26</xref> DNA samples on the DMET Plus array were scanned with the GeneChip Scanner 3000 (Affymetrix Inc.). The genotype profile of 1,931 SNPs was generated by DMET™ Console Software<sup>®</sup> (Version 1.3; Affymetrix Inc.).</p>
</sec>
<sec>
<title>Quality control</title>
<p>Quality control of the samples and SNPs was performed as shown in <xref ref-type="fig" rid="f1-ndt-12-843">Figure 1</xref>. Individual samples were considered passed or in bounds if they had genotyping calls &gt;90%. The markers with genotyping call rate &lt;95%, deviation from Hardy–Weinberg equilibrium (HWE) at <italic>P</italic>&gt;0.001, minor allele frequency (MAF) &lt;0.05, and variants on chromosome X were discarded.</p>
</sec>
<sec sec-type="methods">
<title>Statistical analysis</title>
<p>Data are presented as median and ranges, or as otherwise specified. The Haploview 4.2 software was used for checking HWE, along with MAF, and filtering markers according to the criteria set for quality control.<xref ref-type="bibr" rid="b27-ndt-12-843">27</xref></p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec sec-type="intro">
<title>Patient characteristics and selection of markers</title>
<p>Most of the participants were males (87.1%) and had a median age of 8.8 years (range 3.3–18.3 years). A total of 1,681 SNPs passed the first quality control filter with call rate of &gt;95%. Only 489 SNPs were included for the assessment of genetic prevalence after considering the quality control filter removing the SNPs that were not in HWE, MAF &lt;0.05, and SNPs on the X chromosome (46 SNPs) (<xref ref-type="fig" rid="f1-ndt-12-843">Figure 1</xref>). The average call rate of the sample was 99.23%.</p>
</sec>
<sec>
<title>Allele frequency distribution of common functional polymorphisms of Phase I enzymes</title>
<p>The observed minor allele frequencies of common polymorphisms in CYP enzymes with their clinical or functional relevance are presented in <xref ref-type="table" rid="t1-ndt-12-843">Table 1</xref>. We identified 32 CYP genes with different markers prevalent in the Thai population. The prevalence rates of some pharmacologically and clinically relevant CYP polymorphisms observed were as follows: <italic>CYP1A1*2C</italic> (30.3%), <italic>CYP1A2*1C</italic> (30.3%), <italic>CYP1A2*1F</italic> (23.9%), <italic>CYP2A6*9</italic> (15.3%), <italic>CYP2B6*4</italic> (32.8%), <italic>CYP2B6*6</italic> (28.4%), <italic>CYP2C19*2</italic> (33.2%), <italic>CYP2C19*3</italic> (5%), <italic>CYP2D6</italic> 100C&gt;T (41.2%), <italic>CYP2D6</italic> 2850C&gt;T (10.1%), <italic>CYP3A5*3</italic> (37%), and <italic>CYP3A7*2</italic> (35.8%).</p>
</sec>
<sec>
<title>Allele frequency distribution of common functional polymorphisms of Phase II DMEs</title>
<p>We detected different allele frequencies of common Phase II DMEs, with a wide frequency range from 5% to 49% in this Thai population, as shown in <xref ref-type="table" rid="t2-ndt-12-843">Table 2</xref>. Among <italic>UGT1A1</italic> polymorphisms, <italic>UGT1A1</italic>*<italic>60</italic> was the most prevalent (36.1%) in this study group. The prevalence rates of other notable clinically significant variants among several Phase II enzymes were as follows: <italic>UGT2B7</italic>*<italic>2</italic> (31.5%), <italic>UGT1A7</italic>*<italic>12</italic> (15.1%), <italic>GSTA5</italic> c.−31+2057C&gt;T (35.7%), <italic>GSTP1</italic>*<italic>B</italic> (27.5%), <italic>GSTZ1</italic> c.94G&gt;A (39.5%), <italic>NAT2</italic>*<italic>13</italic> (45.4%), and <italic>NAT2</italic>*<italic>6</italic> (27.7%).</p>
</sec>
<sec>
<title>Allele frequency distribution of common functional polymorphisms of drug transporters</title>
<p><xref ref-type="table" rid="t3-ndt-12-843">Table 3</xref> shows the allele frequencies of drug transporter genes in Thai population. Among the important efflux ABCB1 transporters, the MAF of <italic>ABCB1</italic> 1236C&gt;T and 3435C&gt;T exhibited prevalence rates of 34.5% and 43.7%, respectively. Other ABC SNPs with clinical relevance exhibited prevalence rates of rs212091 (15.7%), rs717620 (22.3%), rs2273697 (6.7%), rs3740066 (24.3%), and 30.7% for <italic>ABCG2</italic> 421C&gt;A.</p>
<p>The uptake SLC transporters (OCT1, OCT2, OATP1A2, and OATP1B2) were present with at least one variant allele in this study group (data for all variants not shown). Among the OCT1 family, the two variants rs628031 (Val408Met, 1222G&gt;A) and rs1867351 (Ser52Ser, 156T&gt;C) had higher frequency of 33.9% and 31.9%, respectively. The pharmacologically important variants <italic>SLCO1B1</italic>*<italic>1B</italic>, <italic>SLCO1B1</italic>*<italic>5</italic>, and <italic>SLCO1B1</italic>*<italic>17</italic> had frequencies of 26.9%, 12.2%, and 8.4%, respectively.</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In this study population of 119 Thai children and adolescents with ASD, we have reported allele frequency of clinically relevant DMET SNPs. Among the 1,931 markers genotyped by the DMET assay, we detected ~26% of SNPs distributed along the pharmacokinetic genes. Although, 87% of SNPs passed the 95% call rate criteria, many of the SNPs were discarded because they were monomorphic and had a prevalence of &lt;5%. Our study sample was comprised of mostly males (87%), and hence 46 SNPs on the X chromosome were excluded, as well. The SNPs reported in this study could serve as informative data in assessing the potential risk of therapeutic failure or adverse events in the Thai population, where there is little information available about the prevalence of variations across DMET genes. The DMET microarray technique proved to be a powerful tool enabling us to characterize the clinically important genetic variants among DMET genes.</p>
<p>The frequency of some alleles in this study showed similar prevalence with previous studies conducted in the Thai population. The allele frequencies of <italic>CYP2C19</italic>*<italic>3</italic> (PM), <italic>CYP2D6</italic>*<italic>2</italic>, and <italic>CYP2D6</italic>*<italic>10</italic> (decreased enzyme activity) were 5%, 10%, and 41%, respectively, in this study. Similar findings were reported by the group studying <italic>CYP2C19</italic> and <italic>CYP2D6</italic> polymorphisms and tamoxifen efficacy in Thai patients with breast cancer.<xref ref-type="bibr" rid="b28-ndt-12-843">28</xref>
<italic>CYP2C19</italic>*<italic>2</italic>, a PM, which has been shown to cause severe acute adverse drug reactions among Thai children treated with phenobarbital,<xref ref-type="bibr" rid="b29-ndt-12-843">29</xref> showed a higher frequency of 33.2% in this study, which is in line with the previously reported frequency of 27%.<xref ref-type="bibr" rid="b30-ndt-12-843">30</xref>
<italic>CYP2B6</italic> variants, c.516G&gt;T and c.785A&gt;G, which were strongly correlated with plasma efavirenz levels in the Thai population, are not reported in the findings of this study.<xref ref-type="bibr" rid="b31-ndt-12-843">31</xref> Another variant of a major CYP2B6 enzyme, c.64C&gt;T, which is also associated with efavirenz plasma concentration, was present at a frequency of 0.055, which is also reported by the earlier study to occur at similar prevalence of 0.06.</p>
<p>Polymorphisms in Phase II metabolic enzymes and transporters are of clinical significance, because of altered function affecting the drug safety and drug efficacy.<xref ref-type="bibr" rid="b32-ndt-12-843">32</xref> UGT enzyme polymorphisms have been associated with several drug substrates and widely studied among several ethnic groups.<xref ref-type="bibr" rid="b33-ndt-12-843">33</xref>–<xref ref-type="bibr" rid="b35-ndt-12-843">35</xref> The prevalence of <italic>UGT1A1</italic>*<italic>6</italic>, which is more commonly observed in Asian populations and absent among Caucasians, resembled earlier studies that reported a frequency of 9%.<xref ref-type="bibr" rid="b36-ndt-12-843">36</xref> A previous study of <italic>UGT2B7</italic>*<italic>2</italic> among Thai patients with breast cancer reported an allele frequency of 28%,<xref ref-type="bibr" rid="b37-ndt-12-843">37</xref> which is similar to the 31.5% reported in this study. <italic>CYP1A2</italic>*<italic>1F</italic> was associated with an increased risk of cholangiocarcinoma (CCA), while <italic>NAT2</italic>*<italic>6</italic> and *<italic>7</italic> were associated with a lower risk of CCA in a study by Prawan et al,<xref ref-type="bibr" rid="b38-ndt-12-843">38</xref> who evaluated the relationship between <italic>CYP1A2</italic> and <italic>NAT2</italic> alleles and CCA among individuals living in the northeastern region of Thailand. The allelic frequencies of <italic>CYP1A2</italic>*<italic>1F</italic>, <italic>NAT2</italic>*<italic>6</italic>, and <italic>NAT2</italic>*<italic>7</italic> in this study group were found to be 23.9%, 27.7%, and 17.6%, respectively. Genetic variants of a widely documented polymorphic enzyme TPMT did not pass quality control in this study group with the exception of one variant, <italic>TPMT</italic>_c.474C&gt;T, with a prevalence of 22.7% (data not shown).</p>
<p>Among the genetic polymorphisms of <italic>ABC</italic> and <italic>SLC</italic> transporters, we found a modest replication of allele frequency, as was reported in a previous comprehensive study of the frequency of several functional variants known to affect plasma concentration of anti-human immunodeficiency virus drugs among the Thai population, including <italic>ABCB1</italic> (1236C&gt;T, 2677G&gt;T, and 3435C&gt;T), <italic>ABCG2</italic> 421C&gt;A, and <italic>SLCO1B1</italic> 521T&gt;C.<xref ref-type="bibr" rid="b39-ndt-12-843">39</xref></p>
<p>Limitations in this study include lack of validation data for the markers extracted from the DMET assay. Second, we did not evaluate the clinical role of DMET SNPs in determining the influence on the ASD symptoms. A study by Jiao et al<xref ref-type="bibr" rid="b40-ndt-12-843">40</xref> has accumulated the evidence of the role of SNPs in the classification of symptom severities among ASD children. It is necessary to analyze the effects of genetic polymorphisms in DMET genes on clinical efficacy and adverse events to amplify the strength of this study. Finally, the small size and inability to compare with the diverse ethnic Thai populations may limit the scope of application of our findings. Further inclusion of control population would have provided more evidence for translating the findings from this study into clinical practice, which was lacking in this study.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>In this study, we have analyzed the DMET SNPs that are increasingly significant in identifying the predicted drug metabolizer phenotypes among individuals. Knowledge of these variations and implementation of this information to correlate these variants with drug response in the Thai population will help us to understand the interindividual variations in response to pharmacological agents. Identification of several functional SNPs in the clinical setting, rather than just the few widely studied SNPs, will provide more concise and predictive value for pharmacotherapy.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was supported by grants from the following organizations: 1) Pharmacogenomics for Autistic Child Project, Khoon Poom Foundation, the Project of Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee; 2) Office of the National Research Council of Thailand; 3) Faculty of Medicine Ramathibodi Hospital; and 4) Mahidol University. The authors thank all staff in Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital and all the children and adolescents with ASD who participated in this study.</p>
</ack>
<fn-group>
<fn>
<p>
<bold>Disclosure</bold>
</p>
<p>The authors report no conflicts of interest in this work.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="b1-ndt-12-843">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>You</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic evidence for possible involvement of the calcium channel gene CACNA1A in autism pathogenesis in Chinese Han population</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<issue>11</issue>
<fpage>e0142887</fpage>
<pub-id pub-id-type="pmid">26566276</pub-id>
</element-citation>
</ref>
<ref id="b2-ndt-12-843">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose’meyer</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders</article-title>
<source/>Mol Autism
          <year>2013</year>
<volume>4</volume>
<issue>1</issue>
<fpage>37</fpage>
<pub-id pub-id-type="pmid">24103554</pub-id>
</element-citation>
</ref>
<ref id="b3-ndt-12-843">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mezzelani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raggi</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Marabotti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Milanesi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Ochratoxin A as possible factor trigging autism and its male prevalence via epigenetic mechanism</article-title>
<source/>Nutr Neurosci
          <year>2016</year>
<volume>19</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">25597866</pub-id>
</element-citation>
</ref>
<ref id="b4-ndt-12-843">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tordjman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaafari</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Aripiprazole for treating irritability in children &amp; adolescents with autism: a systematic review</article-title>
<source/>Indian J Med Res
          <year>2015</year>
<volume>142</volume>
<issue>3</issue>
<fpage>269</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="pmid">26458342</pub-id>
</element-citation>
</ref>
<ref id="b5-ndt-12-843">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McQuire</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hassiotis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pilling</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis</article-title>
<source/>BMC Psychiatry
          <year>2015</year>
<volume>15</volume>
<issue>1</issue>
<fpage>303</fpage>
<pub-id pub-id-type="pmid">26611280</pub-id>
</element-citation>
</ref>
<ref id="b6-ndt-12-843">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hongkaew</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ngamsamut</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Puangpetch</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone</article-title>
<source/>Neuropsychiatr Dis Treat
          <year>2015</year>
<volume>11</volume>
<fpage>191</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">25653528</pub-id>
</element-citation>
</ref>
<ref id="b7-ndt-12-843">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benvenuto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Battan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Porfirio</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Pharmacotherapy of autism spectrum disorders</article-title>
<source/>Brain Dev
          <year>2013</year>
<volume>35</volume>
<issue>2</issue>
<fpage>119</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">22541665</pub-id>
</element-citation>
</ref>
<ref id="b8-ndt-12-843">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapedanovska Nestorovska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jakovski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Naumovska</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distribution of the most common genetic variants associated with a variable drug response in the population of the Republic of Macedonia</article-title>
<source/>Balkan J Med Genet
          <year>2014</year>
<volume>17</volume>
<issue>2</issue>
<fpage>5</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">25937793</pub-id>
</element-citation>
</ref>
<ref id="b9-ndt-12-843">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>AY</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics, pharmacogenomics, and individualized medicine</article-title>
<source/>Pharmacol Rev
          <year>2011</year>
<volume>63</volume>
<issue>2</issue>
<fpage>437</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">21436344</pub-id>
</element-citation>
</ref>
<ref id="b10-ndt-12-843">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift</article-title>
<source/>Indian J Pharm Sci
          <year>2015</year>
<volume>77</volume>
<issue>2</issue>
<fpage>135</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">26009644</pub-id>
</element-citation>
</ref>
<ref id="b11-ndt-12-843">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mango</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vecchione</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Raso</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy</article-title>
<source/>Expert Opin Pharmacother
          <year>2005</year>
<volume>6</volume>
<issue>15</issue>
<fpage>2565</fpage>
<lpage>2576</lpage>
<pub-id pub-id-type="pmid">16316297</pub-id>
</element-citation>
</ref>
<ref id="b12-ndt-12-843">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Spurr</surname>
<given-names>NK</given-names>
</name>
</person-group>
<article-title>Single nucleotide polymorphisms as tools in human genetics</article-title>
<source/>Hum Mol Genet
          <year>2000</year>
<volume>9</volume>
<issue>16</issue>
<fpage>2403</fpage>
<lpage>2408</lpage>
<pub-id pub-id-type="pmid">11005795</pub-id>
</element-citation>
</ref>
<ref id="b13-ndt-12-843">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhary</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases</article-title>
<source/>Drug Metab Rev
          <year>2015</year>
<volume>47</volume>
<issue>3</issue>
<fpage>281</fpage>
<lpage>290</lpage>
</element-citation>
</ref>
<ref id="b14-ndt-12-843">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression</article-title>
<source/>Biol Psychiatry
          <year>2003</year>
<volume>54</volume>
<issue>10</issue>
<fpage>953</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">14625137</pub-id>
</element-citation>
</ref>
<ref id="b15-ndt-12-843">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braam</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Keijzer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Struijker Boudier</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Didden</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Curfs</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder?</article-title>
<source/>J Intellect Disabil Res
          <year>2013</year>
<volume>57</volume>
<issue>11</issue>
<fpage>993</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="pmid">22823064</pub-id>
</element-citation>
</ref>
<ref id="b16-ndt-12-843">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karam</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Rezk</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Abdelrahman</surname>
<given-names>HM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Catechol-O-methyltransferase Val158Met polymorphism and hyperactivity symptoms in Egyptian children with autism spectrum disorder</article-title>
<source/>Res Dev Disabil
          <year>2013</year>
<volume>34</volume>
<issue>7</issue>
<fpage>2092</fpage>
<lpage>2097</lpage>
<pub-id pub-id-type="pmid">23643763</pub-id>
</element-citation>
</ref>
<ref id="b17-ndt-12-843">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umamaheswaran</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Adithan</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes &amp; drug transporters – a review with Indian perspective</article-title>
<source/>Indian J Med Res
          <year>2014</year>
<volume>139</volume>
<issue>1</issue>
<fpage>27</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">24604039</pub-id>
</element-citation>
</ref>
<ref id="b18-ndt-12-843">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bluth</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy</article-title>
<source/>Pharmgenomics Pers Med
          <year>2011</year>
<volume>4</volume>
<fpage>11</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">23226051</pub-id>
</element-citation>
</ref>
<ref id="b19-ndt-12-843">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sim</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kacevska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ingelman-Sundberg</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects</article-title>
<source/>Pharmacogenomics J
          <year>2013</year>
<volume>13</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">23089672</pub-id>
</element-citation>
</ref>
<ref id="b20-ndt-12-843">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonifaz-Pena</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Contreras</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Struchiner</surname>
<given-names>CJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>11</issue>
<fpage>e112640</fpage>
<pub-id pub-id-type="pmid">25419701</pub-id>
</element-citation>
</ref>
<ref id="b21-ndt-12-843">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression variability in human hepatic drug metabolizing enzymes and transporters</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>4</issue>
<fpage>e60368</fpage>
<pub-id pub-id-type="pmid">23637747</pub-id>
</element-citation>
</ref>
<ref id="b22-ndt-12-843">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jittikoon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mahasirimongkol</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Charoenyingwattana</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations</article-title>
<source/>J Hum Genet
          <comment>Epub</comment>
<year>2015</year>
<month>10</month>
<day>1</day>
</element-citation>
</ref>
<ref id="b23-ndt-12-843">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saldivar</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sugarman</surname>
<given-names>EA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility</article-title>
<source/>Pharmacogenomics Pers Med
          <year>2016</year>
<volume>9</volume>
<fpage>1</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="b24-ndt-12-843">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Concordance of DMET plus genotyping results with those of orthogonal genotyping methods</article-title>
<source/>Clin Pharmacol Ther
          <year>2012</year>
<volume>92</volume>
<issue>3</issue>
<fpage>360</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="pmid">22871999</pub-id>
</element-citation>
</ref>
<ref id="b25-ndt-12-843">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardenbol</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiplexed genotyping with sequence-tagged molecular inversion probes</article-title>
<source/>Nat Biotechnol
          <year>2003</year>
<volume>21</volume>
<issue>6</issue>
<fpage>673</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="pmid">12730666</pub-id>
</element-citation>
</ref>
<ref id="b26-ndt-12-843">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syvanen</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Toward genome-wide SNP genotyping</article-title>
<source/>Nat Genet
          <year>2005</year>
<volume>37</volume>
<issue>suppl</issue>
<fpage>S5</fpage>
<lpage>S10</lpage>
<pub-id pub-id-type="pmid">15920530</pub-id>
</element-citation>
</ref>
<ref id="b27-ndt-12-843">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Fry</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title>
<source/>Bioinformatics
          <year>2005</year>
<volume>21</volume>
<issue>2</issue>
<fpage>263</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="pmid">15297300</pub-id>
</element-citation>
</ref>
<ref id="b28-ndt-12-843">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamnanphon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pechatanan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sirachainan</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen</article-title>
<source/>Pharmgenomics Pers Med
          <year>2013</year>
<volume>6</volume>
<fpage>37</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">23776391</pub-id>
</element-citation>
</ref>
<ref id="b29-ndt-12-843">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manuyakorn</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Siripool</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kamchaisatian</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children</article-title>
<source/>Pediatr Allergy Immunol
          <year>2013</year>
<volume>24</volume>
<issue>3</issue>
<fpage>299</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="pmid">23551241</pub-id>
</element-citation>
</ref>
<ref id="b30-ndt-12-843">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassaneeyakul</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tawalee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kukongviriyapan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Blaisdell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gaysornsiri</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Analysis of the CYP2C19 polymorphism in a North-eastern Thai population</article-title>
<source/>Pharmacogenetics
          <year>2002</year>
<volume>12</volume>
<issue>3</issue>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">11927837</pub-id>
</element-citation>
</ref>
<ref id="b31-ndt-12-843">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sukasem</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chamnanphon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koomdee</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections</article-title>
<source/>Drug Metab Pharmacokinet
          <year>2013</year>
<volume>28</volume>
<issue>5</issue>
<fpage>391</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="pmid">23399569</pub-id>
</element-citation>
</ref>
<ref id="b32-ndt-12-843">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yiannakopoulou</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications</article-title>
<source/>Pharmacogenomics J
          <year>2013</year>
<volume>13</volume>
<issue>2</issue>
<fpage>105</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">23044602</pub-id>
</element-citation>
</ref>
<ref id="b33-ndt-12-843">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cote</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Kirzin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kramar</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan</article-title>
<source/>Clin Cancer Res
          <year>2007</year>
<volume>13</volume>
<issue>11</issue>
<fpage>3269</fpage>
<lpage>3275</lpage>
<pub-id pub-id-type="pmid">17510208</pub-id>
</element-citation>
</ref>
<ref id="b34-ndt-12-843">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients</article-title>
<source/>Cancer Chemother Pharmacol
          <year>2014</year>
<volume>73</volume>
<issue>4</issue>
<fpage>779</fpage>
<lpage>788</lpage>
<pub-id pub-id-type="pmid">24519753</pub-id>
</element-citation>
</ref>
<ref id="b35-ndt-12-843">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lankisch</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Moebius</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Wehmeier</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype</article-title>
<source/>Hepatology
          <year>2006</year>
<volume>44</volume>
<issue>5</issue>
<fpage>1324</fpage>
<lpage>1332</lpage>
<pub-id pub-id-type="pmid">17058217</pub-id>
</element-citation>
</ref>
<ref id="b36-ndt-12-843">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sukasem</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Atasilp</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chansriwong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chamnanphon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puangpetch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sirachainan</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Development of pyrosequencing method for detection of UGT1A1 polymorphisms in Thai colorectal cancers</article-title>
<source/>J Clin Lab Anal
          <year>2016</year>
<volume>30</volume>
<issue>1</issue>
<fpage>84</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">25545261</pub-id>
</element-citation>
</ref>
<ref id="b37-ndt-12-843">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Areepium</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Panomvana</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rungwanonchai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sathaporn</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Voravud</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients</article-title>
<source/>Breast Cancer (Dove Med Press)
          <year>2013</year>
<volume>5</volume>
<fpage>73</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">24648760</pub-id>
</element-citation>
</ref>
<ref id="b38-ndt-12-843">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prawan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kukongviriyapan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Tassaneeyakul</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pairojkul</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bhudhisawasdi</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma</article-title>
<source/>Eur J Cancer Prev
          <year>2005</year>
<volume>14</volume>
<issue>3</issue>
<fpage>245</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="pmid">15901993</pub-id>
</element-citation>
</ref>
<ref id="b39-ndt-12-843">
<label>39</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Chaikan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chierakul</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saguenwong</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<source/>Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugs
          <conf-name>Ninth International Congress on Drug Therapy in HIV Infection</conf-name>
<conf-date>2008</conf-date>
<conf-loc>Glasgow</conf-loc>
</element-citation>
</ref>
<ref id="b40-ndt-12-843">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single nucleotide polymorphisms predict symptom severity of autism spectrum disorder</article-title>
<source/>J Autism Dev Disord
          <year>2012</year>
<volume>42</volume>
<issue>6</issue>
<fpage>971</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="pmid">21786105</pub-id>
</element-citation>
</ref>
<ref id="b41-ndt-12-843">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine</article-title>
<source/>J Cancer Res Clin Oncol
          <year>2012</year>
<volume>138</volume>
<issue>7</issue>
<fpage>1197</fpage>
<lpage>1203</lpage>
<pub-id pub-id-type="pmid">22426923</pub-id>
</element-citation>
</ref>
<ref id="b42-ndt-12-843">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>KU</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios</article-title>
<source/>Eur J Clin Pharmacol
          <year>2006</year>
<volume>62</volume>
<issue>8</issue>
<fpage>627</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="pmid">16841220</pub-id>
</element-citation>
</ref>
<ref id="b43-ndt-12-843">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiwari</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Deshpande</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism</article-title>
<source/>Pharmacogenomics J
          <year>2005</year>
<volume>5</volume>
<issue>1</issue>
<fpage>60</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">15505641</pub-id>
</element-citation>
</ref>
<ref id="b44-ndt-12-843">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laika</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leucht</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heres</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Steimer</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome</article-title>
<source/>Pharmacogenomics J
          <year>2010</year>
<volume>10</volume>
<issue>1</issue>
<fpage>20</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">19636338</pub-id>
</element-citation>
</ref>
<ref id="b45-ndt-12-843">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Kwara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>DM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes</article-title>
<source/>J Antimicrob Chemother
          <year>2014</year>
<volume>69</volume>
<issue>8</issue>
<fpage>2175</fpage>
<lpage>2182</lpage>
<pub-id pub-id-type="pmid">24729586</pub-id>
</element-citation>
</ref>
<ref id="b46-ndt-12-843">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manosuthi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sukasem</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lueangniyomkul</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients</article-title>
<source/>Antimicrob Agents Chemother
          <year>2013</year>
<volume>57</volume>
<issue>2</issue>
<fpage>1019</fpage>
<lpage>1024</lpage>
<pub-id pub-id-type="pmid">23254426</pub-id>
</element-citation>
</ref>
<ref id="b47-ndt-12-843">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukonzo</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Nanzigu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Waako</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ogwal-Okeng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gustafson</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Aklillu</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<issue>11</issue>
<fpage>1423</fpage>
<lpage>1435</lpage>
<pub-id pub-id-type="pmid">25303294</pub-id>
</element-citation>
</ref>
<ref id="b48-ndt-12-843">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Weide</surname>
<given-names>J</given-names>
</name>
<name>
<surname>van Baalen-Benedek</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Kootstra-Ros</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype</article-title>
<source/>Ther Drug Monit
          <year>2005</year>
<volume>27</volume>
<issue>4</issue>
<fpage>478</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">16044105</pub-id>
</element-citation>
</ref>
<ref id="b49-ndt-12-843">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Correlation between SNPs in candidate genes and VerifyNow-detected platelet responsiveness to aspirin and clopidogrel treatment</article-title>
<source/>Cardiovasc Drugs Ther
          <year>2015</year>
<volume>29</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">25860557</pub-id>
</element-citation>
</ref>
<ref id="b50-ndt-12-843">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horenstein</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Madabushi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zineh</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers</article-title>
<source/>J Clin Pharmacol
          <year>2014</year>
<volume>54</volume>
<issue>8</issue>
<fpage>865</fpage>
<lpage>873</lpage>
<pub-id pub-id-type="pmid">24710841</pub-id>
</element-citation>
</ref>
<ref id="b51-ndt-12-843">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudberg</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hermann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Refsum</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Molden</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients</article-title>
<source/>Eur J Clin Pharmacol
          <year>2008</year>
<volume>64</volume>
<issue>12</issue>
<fpage>1181</fpage>
<lpage>1188</lpage>
<pub-id pub-id-type="pmid">18677622</pub-id>
</element-citation>
</ref>
<ref id="b52-ndt-12-843">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tybring</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lindh</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis</article-title>
<source/>Clin Pharmacokinet
          <year>2014</year>
<volume>53</volume>
<issue>9</issue>
<fpage>801</fpage>
<lpage>811</lpage>
<pub-id pub-id-type="pmid">25154506</pub-id>
</element-citation>
</ref>
<ref id="b53-ndt-12-843">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Penas-Lledo</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Trejo</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Dorado</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline mono-therapy treatment in major depressive patients</article-title>
<source/>Mol Psychiatry
          <year>2013</year>
<volume>18</volume>
<issue>1</issue>
<fpage>8</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22733128</pub-id>
</element-citation>
</ref>
<ref id="b54-ndt-12-843">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects</article-title>
<source/>Eur J Clin Pharmacol
          <year>2014</year>
<volume>70</volume>
<issue>1</issue>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">24077935</pub-id>
</element-citation>
</ref>
<ref id="b55-ndt-12-843">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodgson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tansey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dernovsek</surname>
<given-names>MZ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic differences in cytochrome P450 enzymes and antidepressant treatment response</article-title>
<source/>J Psychopharmacol
          <year>2014</year>
<volume>28</volume>
<issue>2</issue>
<fpage>133</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">24257813</pub-id>
</element-citation>
</ref>
<ref id="b56-ndt-12-843">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurica</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zourkova</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Dynamics and persistence of CYP2D6 inhibition by paroxetine</article-title>
<source/>J Clin Pharm Ther
          <year>2013</year>
<volume>38</volume>
<issue>4</issue>
<fpage>294</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">23437966</pub-id>
</element-citation>
</ref>
<ref id="b57-ndt-12-843">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchheiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Keulen</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Roots</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brockmoller</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol</article-title>
<source/>J Clin Psychopharmacol
          <year>2008</year>
<volume>28</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">18204346</pub-id>
</element-citation>
</ref>
<ref id="b58-ndt-12-843">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nair</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Sarasamma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gracious</surname>
<given-names>N</given-names>
</name>
<name>
<surname>George</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Anish</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Radhakrishnan</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level</article-title>
<source/>Exp Clin Transplant
          <year>2015</year>
<volume>13</volume>
<issue>suppl 1</issue>
<fpage>197</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">25894154</pub-id>
</element-citation>
</ref>
<ref id="b59-ndt-12-843">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birdwell</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Grady</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients</article-title>
<source/>Pharmacogenet Genomics
          <year>2012</year>
<volume>22</volume>
<issue>1</issue>
<fpage>32</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">22108237</pub-id>
</element-citation>
</ref>
<ref id="b60-ndt-12-843">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>KS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects</article-title>
<source/>Clin Pharmacol Ther
          <year>2008</year>
<volume>83</volume>
<issue>4</issue>
<fpage>595</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">17687269</pub-id>
</element-citation>
</ref>
<ref id="b61-ndt-12-843">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takekuma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takenaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kiyokawa</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis</article-title>
<source/>Biol Pharm Bull
          <year>2007</year>
<volume>30</volume>
<issue>3</issue>
<fpage>537</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">17329852</pub-id>
</element-citation>
</ref>
<ref id="b62-ndt-12-843">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ten Brink</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Swen</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bohringer</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients</article-title>
<source/>Pharmacogenet Genomics
          <year>2013</year>
<volume>23</volume>
<issue>12</issue>
<fpage>675</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="pmid">24192531</pub-id>
</element-citation>
</ref>
<ref id="b63-ndt-12-843">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>BN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer</article-title>
<source/>Chin Med J (Engl)
          <year>2011</year>
<volume>124</volume>
<issue>2</issue>
<fpage>199</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">21362365</pub-id>
</element-citation>
</ref>
<ref id="b64-ndt-12-843">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamas</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Duran</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Balboa</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer</article-title>
<source/>Pharmacogenomics
          <year>2011</year>
<volume>12</volume>
<issue>3</issue>
<fpage>433</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="pmid">21449681</pub-id>
</element-citation>
</ref>
<ref id="b65-ndt-12-843">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shroads</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Langaee</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Coats</surname>
<given-names>BS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate</article-title>
<source/>J Clin Pharmacol
          <year>2012</year>
<volume>52</volume>
<issue>6</issue>
<fpage>837</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="pmid">21642471</pub-id>
</element-citation>
</ref>
<ref id="b66-ndt-12-843">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Amarapurkar</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India</article-title>
<source/>J Gastroenterol Hepatol
          <year>2013</year>
<volume>28</volume>
<issue>8</issue>
<fpage>1368</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="pmid">23875638</pub-id>
</element-citation>
</ref>
<ref id="b67-ndt-12-843">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verhagen</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Coenen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<issue>3</issue>
<fpage>285</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="pmid">24533708</pub-id>
</element-citation>
</ref>
<ref id="b68-ndt-12-843">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<issue>8</issue>
<fpage>897</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="pmid">23746184</pub-id>
</element-citation>
</ref>
<ref id="b69-ndt-12-843">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aarnoudse</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Dieleman</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>LE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration</article-title>
<source/>Pharmacogenet Genomics
          <year>2008</year>
<volume>18</volume>
<issue>4</issue>
<fpage>299</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="pmid">18334914</pub-id>
</element-citation>
</ref>
<ref id="b70-ndt-12-843">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciccacci</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Borgiani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ceffa</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique</article-title>
<source/>Pharmacogenomics
          <year>2010</year>
<volume>11</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">20017669</pub-id>
</element-citation>
</ref>
<ref id="b71-ndt-12-843">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caronia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Patino-Garcia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perez-Martinez</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>10</issue>
<fpage>e26091</fpage>
<pub-id pub-id-type="pmid">22016816</pub-id>
</element-citation>
</ref>
<ref id="b72-ndt-12-843">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coelho</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>de Alencar</surname>
<given-names>LC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients</article-title>
<source/>J Clin Pharmacol
          <year>2013</year>
<volume>53</volume>
<issue>12</issue>
<fpage>1286</fpage>
<lpage>1293</lpage>
<pub-id pub-id-type="pmid">23996099</pub-id>
</element-citation>
</ref>
<ref id="b73-ndt-12-843">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>JY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients</article-title>
<source/>CNS Neurosci Ther
          <year>2012</year>
<volume>18</volume>
<issue>8</issue>
<fpage>647</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="pmid">22630058</pub-id>
</element-citation>
</ref>
<ref id="b74-ndt-12-843">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franke</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Lancaster</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Peer</surname>
<given-names>CJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of ABCC2 (MRP2) transport function on erythromycin metabolism</article-title>
<source/>Clin Pharmacol Ther
          <year>2011</year>
<volume>89</volume>
<issue>5</issue>
<fpage>693</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="pmid">21451505</pub-id>
</element-citation>
</ref>
<ref id="b75-ndt-12-843">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>SW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer</article-title>
<source/>Cancer Chemother Pharmacol
          <year>2013</year>
<volume>71</volume>
<issue>4</issue>
<fpage>843</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="pmid">23314736</pub-id>
</element-citation>
</ref>
<ref id="b76-ndt-12-843">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haenisch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>May</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wegner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Caliebe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cascorbi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Siegmund</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol</article-title>
<source/>Pharmacogenet Genomics
          <year>2008</year>
<volume>18</volume>
<issue>4</issue>
<fpage>357</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="pmid">18334920</pub-id>
</element-citation>
</ref>
<ref id="b77-ndt-12-843">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagashima</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)</article-title>
<source/>Biol Pharm Bull
          <year>2008</year>
<volume>31</volume>
<issue>11</issue>
<fpage>2137</fpage>
<lpage>2142</lpage>
<pub-id pub-id-type="pmid">18981587</pub-id>
</element-citation>
</ref>
<ref id="b78-ndt-12-843">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeGorter</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Tirona</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>UI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care</article-title>
<source/>Circ Cardiovasc Genet
          <year>2013</year>
<volume>6</volume>
<issue>4</issue>
<fpage>400</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="pmid">23876492</pub-id>
</element-citation>
</ref>
<ref id="b79-ndt-12-843">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lui</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Tomlinson</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<issue>11</issue>
<fpage>1283</fpage>
<lpage>1294</lpage>
<pub-id pub-id-type="pmid">23930675</pub-id>
</element-citation>
</ref>
<ref id="b80-ndt-12-843">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Paolo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Polillo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Capecchi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The c.480C&gt;G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia</article-title>
<source/>Pharmacogenomics J
          <year>2014</year>
<volume>14</volume>
<issue>4</issue>
<fpage>328</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">24589908</pub-id>
</element-citation>
</ref>
<ref id="b81-ndt-12-843">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarasova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kalnina</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Geldnere</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients</article-title>
<source/>Pharmacogenet Genomics
          <year>2012</year>
<volume>22</volume>
<issue>9</issue>
<fpage>659</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="pmid">22735389</pub-id>
</element-citation>
</ref>
<ref id="b82-ndt-12-843">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niemi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Neuvonen</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hofmann</surname>
<given-names>U</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17</article-title>
<source/>Pharmacogenet Genomics
          <year>2005</year>
<volume>15</volume>
<issue>5</issue>
<fpage>303</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="pmid">15864131</pub-id>
</element-citation>
</ref>
<ref id="b83-ndt-12-843">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niemi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaeffeler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)</article-title>
<source/>Pharmacogenetics
          <year>2004</year>
<volume>14</volume>
<issue>7</issue>
<fpage>429</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="pmid">15226675</pub-id>
</element-citation>
</ref>
<ref id="b84-ndt-12-843">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunham</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Lansberg</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin</article-title>
<source/>Pharmacogenomics J
          <year>2012</year>
<volume>12</volume>
<issue>3</issue>
<fpage>233</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="pmid">21243006</pub-id>
</element-citation>
</ref>
<ref id="b85-ndt-12-843">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>SEARCH Collaborative Group</collab>
<name>
<surname>Link</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Parish</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SLCO1B1 variants and statin-induced myopathy – a genomewide study</article-title>
<source/>N Engl J Med
          <year>2008</year>
<volume>359</volume>
<issue>8</issue>
<fpage>789</fpage>
<lpage>799</lpage>
<pub-id pub-id-type="pmid">18650507</pub-id>
</element-citation>
</ref>
<ref id="b86-ndt-12-843">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marciante</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Durda</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Heckbert</surname>
<given-names>SR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerivastatin, genetic variants, and the risk of rhabdomyolysis</article-title>
<source/>Pharmacogenet Genomics
          <year>2011</year>
<volume>21</volume>
<issue>5</issue>
<fpage>280</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">21386754</pub-id>
</element-citation>
</ref>
<ref id="b87-ndt-12-843">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants</article-title>
<source/>Pharmacogenet Genomics
          <year>2007</year>
<volume>17</volume>
<issue>8</issue>
<fpage>647</fpage>
<lpage>656</lpage>
<pub-id pub-id-type="pmid">17622941</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ndt-12-843" position="float">
<label>Figure 1</label>
<caption>
<p>Flow diagram of genetic marker selection.</p>
<p><bold>Abbreviations:</bold> DMET, drug-metabolizing enzymes and transporters; HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; SNPs, single-nucleotide polymorphisms.</p>
</caption>
<graphic xlink:href="ndt-12-843Fig1"></graphic>
</fig>
<table-wrap id="t1-ndt-12-843" position="float">
<label>Table 1</label>
<caption>
<p>Minor allele frequencies of common functional polymorphisms in major human <italic>CYP</italic> genes in Thai children and adolescents with autism spectrum disorder (sample size =119)</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">dbSNP RS ID</th>
<th align="left" colspan="1" rowspan="1" valign="top">Common name</th>
<th align="left" colspan="1" rowspan="1" valign="top">Minor allele frequency</th>
<th align="left" colspan="1" rowspan="1" valign="top">Clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP1A1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1048943<break></break>rs4646422</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP1A1*2C</italic>_2454A&gt;G(I462V)<break></break><italic>CYP1A1</italic>_134G&gt;A(G45D)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.303<break></break>0.08</td>
<td align="left" colspan="1" rowspan="1" valign="top">• In *<italic>2C</italic> variant, the AA genotype has decreased progression-free survival time compared to AG and GG genotypes in women with breast cancer treated with capecitabine and docetaxel<xref ref-type="bibr" rid="b41-ndt-12-843">41</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP1A2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs2069514<break></break>rs762551<break></break>rs2470890</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP1A2*1C</italic>_−3860G&gt;A(Promoter)<break></break><italic>CYP1A2*1F</italic>_−163C&gt;A(Promoter)<break></break><italic>CYP1A2</italic>_5347T&gt;C(N516N)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.303<break></break>0.239<break></break>0.206</td>
<td align="left" colspan="1" rowspan="1" valign="top">• Genotypes AA and AG are associated with decreased metabolism of theophylline as compared to genotype GG in patients with asthma for *<italic>1C</italic><xref ref-type="bibr" rid="b42-ndt-12-843">42</xref><break></break>• Allele A is associated with tardive dyskinesia in patients taking antipsychotic medications compared to allele G among smokers for *<italic>1C</italic> polymorphism<xref ref-type="bibr" rid="b43-ndt-12-843">43</xref><break></break>• Patients with *<italic>1F</italic> variants are associated with reduced serum concentration of olanzapine and subsequent decreased response<xref ref-type="bibr" rid="b44-ndt-12-843">44</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP2A6</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs28399433<break></break>rs1137115<break></break>rs4079369<break></break>rs8192729</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP2A6*9</italic>_−48T&gt;G(Promoter)<break></break><italic>CYP2A6</italic>_51G&gt;A(V17V)<break></break><italic>CYP2A6</italic>_3570C&gt;G<break></break><italic>CYP2A6</italic>_5336G&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.153<break></break>0.261<break></break>0.076<break></break>0.076</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>CYP2A6</italic>*<italic>9</italic> is associated with increased plasma concentration of efavirenz<xref ref-type="bibr" rid="b45-ndt-12-843">45</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP2B6</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs8192709<break></break>rs4803418<break></break>rs2279343<break></break>rs3745274<break></break>rs2279344<break></break>rs8192719</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP2B6*2</italic>_64C&gt;T(R22C)<break></break><italic>CYP2B6</italic>_14593C&gt;G<break></break><italic>CYP2B6*4</italic>_18053A&gt;G(K262R)<break></break><italic>CYP2B6*6</italic>_15631G&gt;T(Q172H)<break></break><italic>CYP2B6</italic>_18273G&gt;A<break></break><italic>CYP2B6</italic>_21563C&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.055<break></break>0.382<break></break>0.328<break></break>0.284<break></break>0.286<break></break>0.282</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>CYP2B6</italic>*<italic>4</italic> is associated with increased plasma concentration of efavirenz<xref ref-type="bibr" rid="b46-ndt-12-843">46</xref><break></break>• <italic>CYP2B6</italic>*<italic>6</italic> is associated with increased efavirenz plasma concentrations<xref ref-type="bibr" rid="b47-ndt-12-843">47</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP2C19</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs4244285<break></break>rs4986893</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP2C19*2</italic>_19154G&gt;A(P227P)<break></break><italic>CYP2C19*3</italic>_17948G&gt;A(W212X)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.332<break></break>0.05</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>CYP2C19</italic>*<italic>2</italic> and *<italic>3</italic> is known to affect the metabolism and/or responses of several drugs, like amitriptyline, clopidogrel, sertraline, citalopram, and escitalopram<xref ref-type="bibr" rid="b48-ndt-12-843">48</xref>–<xref ref-type="bibr" rid="b52-ndt-12-843">52</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP2D6</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1135840<break></break>rs16947<break></break>rs1058164<break></break>rs1065852<break></break>rs1080985<break></break>rs28360521</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP2D6</italic>_4180G&gt;C(S486T)<break></break><italic>CYP2D6</italic>_2850C&gt;T(R296C)<break></break><italic>CYP2D6</italic>_1661G&gt;C(V136V)<break></break><italic>CYP2D6</italic>_100C&gt;T(P34S)<break></break><italic>CYP2D6</italic>_−1584C&gt;G<break></break><italic>CYP2D6</italic>_−2178G&gt;A</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.298<break></break>0.101<break></break>0.286<break></break>0.412<break></break>0.071<break></break>0.397</td>
<td align="left" colspan="1" rowspan="1" valign="top">• Amitriptyline, nortriptyline, paroxetine, codeine, and tramadol are some of the drugs whose pharmacokinetics, response, and toxicity are known to be influenced by CYP2D6 polymorphisms<xref ref-type="bibr" rid="b53-ndt-12-843">53</xref>–<xref ref-type="bibr" rid="b57-ndt-12-843">57</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP3A5</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs776746</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP3A5*3</italic>_6986A&gt;G(SpliceDefect)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.37</td>
<td align="left" colspan="1" rowspan="1" valign="top">• Patients with *<italic>3/</italic>*<italic>3</italic> genotype show higher concentration of tacrolimus as compared to *<italic>1/</italic>*<italic>1</italic> and *<italic>1/</italic>*<italic>3</italic> genotypes<xref ref-type="bibr" rid="b58-ndt-12-843">58</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>CYP3A7</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs2257401</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>CYP3A7*2</italic>_26041C&gt;G(T409R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.358</td>
<td align="left" colspan="1" rowspan="1" valign="top">• Presence of <italic>CYP3A7</italic>*<italic>2</italic> is associated with higher concentration/dose ratio of tacrolimus<xref ref-type="bibr" rid="b59-ndt-12-843">59</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ndt-12-843">
<p><bold>Note:</bold> dbSNP RS ID is an identification tag assigned by the National Center for Biotechnology Information to a group of single nucelotide polymorphisms (SNPs) that map to an identical location in the SNP database.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t2-ndt-12-843" position="float">
<label>Table 2</label>
<caption>
<p>Minor allele frequencies of common functional polymorphisms in major human Phase II drug-metabolizing enzyme genes in Thai children and adolescents with autism spectrum disorder (sample size =119)</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">dbSNP RS ID</th>
<th align="left" colspan="1" rowspan="1" valign="top">Common name</th>
<th align="left" colspan="1" rowspan="1" valign="top">Minor allele frequency</th>
<th align="left" colspan="1" rowspan="1" valign="top">Clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>UGT1A1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs4148323<break></break>rs4124874<break></break>rs10929303<break></break>rs8330<break></break>rs887829<break></break>rs10929302</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>UGT1A1*6</italic>_c.211G&gt;A(G71R)<break></break><italic>UGT1A1*60</italic>_c.−3279T&gt;G(Promoter)<break></break><italic>UGT1A1*76</italic>_c.*211C&gt;T(3′UTR)<break></break><italic>UGT1A1*79</italic>_c.*440C&gt;G(3′UTR)<break></break><italic>UGT1A1*80</italic>_c.−364C&gt;T<break></break><italic>UGT1A1*93</italic>_c.−3156G&gt;A(Promoter)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.067<break></break>0.361<break></break>0.088<break></break>0.082<break></break>0.13<break></break>0.126</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>UGT1A1</italic>*<italic>6</italic> is associated with increased risk of neutropenia when treated with irinotecan<xref ref-type="bibr" rid="b34-ndt-12-843">34</xref><break></break>• <italic>UGT1A1</italic>*<italic>93</italic> is associated with increased risk of hematologic toxicity in irinotecan-treated patients<xref ref-type="bibr" rid="b33-ndt-12-843">33</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>UGT1A7</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs7586110</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>UGT1A7*12</italic>_c.−57T&gt;G(5′UTR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.151</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>UGT1A7</italic>*<italic>12</italic> is associated with increased risk of hyperbilirubinemia when treated with atazanavir<xref ref-type="bibr" rid="b35-ndt-12-843">35</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>UGT2B7</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs7439366<break></break>rs12233719</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>UGT2B7*2</italic>_c.802C&gt;T(H268Y)<break></break><italic>UGT2B7*3</italic>_c.211G&gt;T(A71S)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.315<break></break>0.084</td>
<td align="left" colspan="1" rowspan="1" valign="top">• Genotype TT shows better response to lorazepam and valproic acid as compared to genotype CC in <italic>UGT2B7</italic>*<italic>2</italic> polymorphism<xref ref-type="bibr" rid="b60-ndt-12-843">60</xref><break></break>• <italic>UGT2B7</italic>*<italic>3</italic> is associated with decreased clearance of carvedilol<xref ref-type="bibr" rid="b61-ndt-12-843">61</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GSTA5</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs4715354<break></break>rs7746993</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>GSTA5</italic>_c.−31+2057C&gt;T<break></break><italic>GSTA5</italic>_−8526G&gt;T</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.357<break></break>0.147</td>
<td align="left" colspan="1" rowspan="1" valign="top">• rs4715354 and rs7746993, both combined, are associated with decreased busulfan clearance<xref ref-type="bibr" rid="b62-ndt-12-843">62</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GSTP1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1695</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>GSTP1*B</italic>_c.313A&gt;G(I105V)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.275</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>GSTP1</italic>*<italic>B</italic> is associated with increased response and decreased severity of toxicity among patients with breast cancer treated with cyclophosphamide and epirubicin<xref ref-type="bibr" rid="b63-ndt-12-843">63</xref><break></break>• Efficacy and/or toxicity of oxaliplatin, methotrexate, and fluorouracil are associated with <italic>GSTP1</italic>*<italic>B</italic> variant<xref ref-type="bibr" rid="b64-ndt-12-843">64</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>GSTZ1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1046428<break></break>rs7975</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>GSTZ1</italic>_c.245C&gt;T(T82M)<break></break><italic>GSTZ1</italic>_c.94G&gt;A(E32K)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.055<break></break>0.395</td>
<td align="left" colspan="1" rowspan="1" valign="top">• rs7975 and rs1046428 are associated with clearance of dichloroacetic acid<xref ref-type="bibr" rid="b65-ndt-12-843">65</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NAT2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1799929<break></break>rs1801280<break></break>rs1799930<break></break>rs1799931<break></break>rs1041983</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>NAT2</italic>_c.481C&gt;T(L161L)<break></break><italic>NAT2*5</italic>_c.341T&gt;C(I114T)<break></break><italic>NAT2*6</italic>_c.590G&gt;A(R197Q)<break></break><italic>NAT2*7</italic>_c.857G&gt;A(G286E)<break></break><italic>NAT2*13</italic>_c.282C&gt;T(Y94Y)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.078<break></break>0.092<break></break>0.277<break></break>0.176<break></break>0.454</td>
<td align="left" colspan="1" rowspan="1" valign="top">• rs1799929 variant is associated with hepatotoxicity when treated with antituberculosis drugs<xref ref-type="bibr" rid="b66-ndt-12-843">66</xref><break></break>• <italic>NAT2</italic>*<italic>5</italic>, *<italic>6</italic>, *<italic>7</italic> and *<italic>13</italic> influence the metabolism of isoniazid<xref ref-type="bibr" rid="b67-ndt-12-843">67</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn2-ndt-12-843">
<p><bold>Note:</bold> dbSNP RS ID is an identification tag assigned by the National Center for Biotechnology Information to a group of single nucelotide polymorphisms (SNPs) that map to an identical location in the SNP database.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t3-ndt-12-843" position="float">
<label>Table 3</label>
<caption>
<p>Minor allele frequencies of common functional polymorphisms of drug transporter genes (<italic>ABC</italic> and <italic>SLC</italic>) in Thai children and adolescents with autism spectrum disorder (sample size =119)</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">dbSNP RS ID</th>
<th align="left" colspan="1" rowspan="1" valign="top">Common name</th>
<th align="left" colspan="1" rowspan="1" valign="top">Minor allele frequency</th>
<th align="left" colspan="1" rowspan="1" valign="top">Clinical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ABCB1 (MDR1)</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1128503<break></break>rs1045642<break></break>rs10276036</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>ABCB1</italic>_c.1236C&gt;T(G412G)<break></break><italic>ABCB1</italic>_c.3435C&gt;T(I1145I)<break></break><italic>ABCB1</italic>_c.IVS9−44A&gt;G</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.345<break></break>0.437<break></break>0.339</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>ABCB1</italic> 1236C&gt;T is associated with overall increased survival period among oxaliplatin-treated patients with colorectal neoplasms<xref ref-type="bibr" rid="b68-ndt-12-843">68</xref><break></break>• <italic>ABCB1</italic> 3435C&gt;T is associated with increased serum concentration of digoxin<xref ref-type="bibr" rid="b69-ndt-12-843">69</xref> and nevirapine-induced hepatotoxicity<xref ref-type="bibr" rid="b70-ndt-12-843">70</xref><break></break>• rs10276036 is associated with increased risk of death in patients with osteosarcoma after chemotherapy<xref ref-type="bibr" rid="b71-ndt-12-843">71</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ABCC1 (MRP1)</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs212091</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>ABCC1</italic>_c.*1512T&gt;C</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.157</td>
<td align="left" colspan="1" rowspan="1" valign="top">• rs212091 is associated with virological failure in antiretroviral drugs therapy<xref ref-type="bibr" rid="b72-ndt-12-843">72</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ABCC2 (MRP2)</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs717620<break></break>rs2273697<break></break>rs3740066</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>ABCC2</italic>_c.−24C&gt;T(5′UTR)<break></break><italic>ABCC2</italic>_c.1249G&gt;A(V417I)<break></break><italic>ABCC2</italic>_c.3972C&gt;T(I1324I)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.223<break></break>0.067<break></break>0.243</td>
<td align="left" colspan="1" rowspan="1" valign="top">• rs717620 and rs3740066 affect the response to antiepileptic drugs<xref ref-type="bibr" rid="b73-ndt-12-843">73</xref><break></break>• rs717620 influences the metabolism of erythromycin<xref ref-type="bibr" rid="b74-ndt-12-843">74</xref> and is associated with toxicity among patients treated with fluorouracil, leucovorin, and oxaliplatin<xref ref-type="bibr" rid="b75-ndt-12-843">75</xref><break></break>• rs2273697 influences the pharmacokinetics of talinol and irinotecan<xref ref-type="bibr" rid="b76-ndt-12-843">76</xref>,<xref ref-type="bibr" rid="b77-ndt-12-843">77</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>ABCG2 (BCRP)</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs2231142</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>ABCG2</italic>_c.421C&gt;A(Q141K)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.307</td>
<td align="left" colspan="1" rowspan="1" valign="top">• rs2231142 is associated with the plasma concentration of rosuvastatin<xref ref-type="bibr" rid="b78-ndt-12-843">78</xref>,<xref ref-type="bibr" rid="b79-ndt-12-843">79</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SLC22A1 (OCT1)</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1867351<break></break>rs683369<break></break>rs2282143<break></break>rs628031</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SLC22A1</italic>_c.156T&gt;C(S52S)<break></break><italic>SLC22A1</italic>_c.480C&gt;G(F160L)<break></break><italic>SLC22A1</italic>_c.1022C&gt;T(P341L)<break></break><italic>SLC22A1</italic>_c.1222G&gt;A(V408M)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.319<break></break>0.148<break></break>0.13<break></break>0.339</td>
<td align="left" colspan="1" rowspan="1" valign="top">• c.480C&gt;G polymorphism is associated with pharmacokinetics of imatinib<xref ref-type="bibr" rid="b80-ndt-12-843">80</xref><break></break>• rs628031 is associated with gastrointestinal side effects when treated with metformin<xref ref-type="bibr" rid="b81-ndt-12-843">81</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SLCO1B1 (OATP1B1)</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs4149015<break></break>rs2306283<break></break>rs4149056<break></break>rs4149057</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>SLCO1B1*17</italic>_c.−11187G&gt;A(Promoter)<break></break><italic>SLCO1B1*1B</italic>_c.388A&gt;G(N130D)<break></break><italic>SLCO1B1*5</italic>_c.521T&gt;C(V174A)<break></break><italic>SLCO1B1</italic>_c.571T&gt;C(L191L)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.084<break></break>0.269<break></break>0.122<break></break>0.282</td>
<td align="left" colspan="1" rowspan="1" valign="top">• <italic>SLCO1B1</italic>*<italic>17</italic> is associated with the efficacy and pharmacokinetics of pravastatin<xref ref-type="bibr" rid="b82-ndt-12-843">82</xref>,<xref ref-type="bibr" rid="b83-ndt-12-843">83</xref><break></break>• <italic>SLCO1B1</italic>*<italic>5</italic> is associated with high risk of muscular diseases when treated with simvastatin<xref ref-type="bibr" rid="b84-ndt-12-843">84</xref>,<xref ref-type="bibr" rid="b85-ndt-12-843">85</xref><break></break>• Other drugs associated with *5 variant include cerivastatin, pravastatin, and rosuvastatin<xref ref-type="bibr" rid="b78-ndt-12-843">78</xref>,<xref ref-type="bibr" rid="b86-ndt-12-843">86</xref>,<xref ref-type="bibr" rid="b87-ndt-12-843">87</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn3-ndt-12-843">
<p><bold>Note:</bold> dbSNP RS ID is an identification tag assigned by the National Center for Biotechnology Information to a group of single nucelotide polymorphisms (SNPs) that map to an identical location in the SNP database.</p>
</fn>
<fn id="tfn4-ndt-12-843">
<p><bold>Abbreviations:</bold> ABC, adenosine triphosphate-binding cassette; SLC, solute carrier.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>